Lemtrada (alemtuzumab) is a medication primarily used to treat relapsing forms of multiple sclerosis (MS). It works by targeting specific immune cells, particularly CD52-positive lymphocytes, leading to their depletion and subsequent modulation of the immune system. Because of its potent…
Lemtrada (alemtuzumab) is a medication used to treat multiple sclerosis (MS), particularly relapsing forms of the disease. One of the critical concerns for many people with MS is difficulty walking, which can result from muscle weakness, spasticity, balance problems, and…
The post-infusion monitoring rules for Lemtrada (alemtuzumab) are critical due to the drug’s potent effects on the immune system and its associated risks. After the infusion, patients require **long-term, careful monitoring for at least 48 months (4 years) following the…
Lemtrada (alemtuzumab) is a medication primarily used to treat multiple sclerosis (MS), especially relapsing-remitting MS. It works by targeting and depleting certain immune cells, which helps reduce the immune system’s attack on the nervous system. However, because it alters immune…
Lemtrada, also known by its generic name alemtuzumab, is a medication primarily used to treat relapsing forms of multiple sclerosis (MS). It works by targeting and depleting certain immune cells that are believed to contribute to the autoimmune attack on…
Lemtrada (alemtuzumab) is a powerful medication used primarily to treat relapsing forms of multiple sclerosis (MS), especially in patients who have not responded well to other treatments. It works by targeting and depleting certain immune cells, specifically CD52-positive lymphocytes, which…
Tysabri (natalizumab) is considered highly effective for treating multiple sclerosis (MS), especially in patients who have not responded well to other disease-modifying therapies (DMTs). When other MS drugs fail to control disease activity, Tysabri often becomes a key option due…
Tysabri (natalizumab) is a medication primarily used to treat multiple sclerosis (MS) and Crohn’s disease by modulating the immune system to reduce inflammation and prevent immune cells from crossing into the brain and spinal cord. When considering whether Tysabri increases…
Tysabri infusions are typically given once every 28 days, which means patients usually receive an intravenous (IV) infusion once a month. This schedule is the standard dosing frequency for Tysabri, although in some cases, depending on individual circumstances and medical…
Tysabri (natalizumab) is a medication used primarily to treat multiple sclerosis (MS) and Crohn’s disease by modifying the immune system. Like many drugs that affect the immune system, Tysabri can cause allergic reactions in some people, although these are not…